Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pathologic response in stage III rectal cancer: chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone
IRCT20210829052320N2Phase 2Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine, folinic acid, fluorouracil and oxaliplatin in rectal adenocarcinoma (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoint: Pathological complete response. Started Nov 2025; status: completed.
02
Drugs
capecitabinefolinic acidfluorouraciloxaliplatin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on IRCT20210829052320N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210829052320N2.